Crenezumab Phase II cognition data in Alzheimer's disease presented

16.July 2014 08:00 CET

English
Franšais
Deutsch

  • Two phase II studies in people with mild-to-moderate Alzheimer's disease over 18 months and a total of 522 patients
  • The proof of concept ABBY study met overall objective of estimating treatment effects and demonstrated positive trends in cognitive endpoints over time, although the study did not meet its co-primary endpoints
  • Larger effects seen in patients with mild disease on high-dose of crenezumab intravenously
  • Acceptable risk benefit profile
  • Next steps to be determined by Roche following further analysis of data